UPDATE 2-HealthCor slams Biogen CEO for outsize pay package

2009年 11月 21日 星期六 04:14 BJT
 

* HealthCor criticizes Biogen CEO paycheck, stock sales

* Calls on company to initiate sustained buyback program

* Says company should cut R&D expenses

(Updates with company comment, share price)

By Toni Clarke

BOSTON, Nov 20 (Reuters) - Biogen Idec Inc (BIIB.O: 行情) shareholder HealthCor Management LP has slammed the biotech company's chief executive for selling more than $85 million of Biogen stock and collecting $63 million in compensation while doing little to enhance the value of the company.

In a letter to CEO James Mullen and the company's board, HealthCor criticized what it says is a disconnect between Mullen's compensation and Biogen's stock performance.

Shares of Biogen, which makes the multiple sclerosis drugs Avonex and Tysabri, are trading in the same range as they were in early 2004. During that time, HealthCor said Mullen has sold roughly half his eligible holdings in Biogen.

"James Mullen has made considerable personal profits while running Biogen Idec and has egregiously continued to sell down his personal holdings in the Company, while investors have been left holding the bag," HealthCor wrote in its letter.

Jennifer Neiman, a spokeswoman for Biogen, said Mullen's stock sales were part of a predetermined stock-selling program and his compensation reflects the fact that in 2008 Biogen exceeded its sales and earnings forecasts.

HealthCor's criticism comes as Biogen struggles to overcome concerns about the safety of its most important drug, Tysabri, which has been associated with a potentially deadly brain infection known as PML.

Biogen stopped publicly announcing new cases of PML at the end of July, raising questions about its disclosure policies. Earlier this month the company, with its partner Elan Corp Plc (ELN.I: 行情) of Ireland, amended the drug's prescribing information to reflect the risk of PML increasing with time.

The drug was temporarily withdrawn from the market in 2005 after being linked with PML. It was reintroduced in July 2006 with stricter safety warnings, but concerns continue to hold back sales.

HealthCor, which owns 3.65 million shares, or 1.3 percent of Biogen, said it has repeatedly called on the company to commit to return cash to shareholders through a long-term stock buyback program of $500 million to $1 billion a year. It said it believes a sustained share repurchase program would be a more accretive use of cash than any near-term acquisitions.

While Biogen recently announced an intended $1 billion share repurchase program, it would not commit to a specific timeframe or additional purchases after that, HealthCor said.

"We believe this "intention" is inadequate, representing further stalling on behalf of the Board and a continuation of the pattern of inaction we have seen over the past year," it said.

HealthCor also said Biogen has failed to maximize its earnings and cash generation potential by focusing too much of its resources on research and development, "an area where the company has had little recent success."

Neiman said Biogen is in fact reducing its R&D spending. On its latest quarterly earnings call it said it had curtailed late-stage clinical trial programs for lumiliximab, its experimental treatment for chronic lymphocytic leukemia, and galiximab, for follicular lymphoma, another blood cancer.

HealthCor is not the first shareholder to attack the company and its management. Earlier this year dissident shareholder Carl Icahn managed to place two directors on Biogen's board following a contentious proxy battle.

Icahn has also accused Cambridge, Massachusetts-based Biogen of sabotaging its own announced attempt to find a buyer.

Biogen's shares were up 55 cents, or 1.2 percent to $46.40 in afternoon trading on Nasdaq. (Reporting by Toni Clarke; editing by Gunna Dickson and Gerald E. McCormick)

 
Facebook想进中国不容易

Facebook申请首次公开募股(IPO),计划融资50亿美元,为其全球增长吹响号角。进军中国市场显然是其伟大抱负的一部分,但成功机率看似不大。 幻灯片 | 全文

 
图片
陆港争议:没有胜利者的口水战

一场突如其来的公众口水战瞬间成为陆港民众关注的焦点。近日内地“双非”孕妇来港产子的争议有升级走向极端情绪化的趋势,令社会各界非常担忧。 专题报道 | 评论

港陆骂战:依法解决是正道
港陆骂战:依法解决是正道

透过香港网民的“蝗虫”广告,可以看清,断断续续、始终不停的港陆骂战,矛盾焦点还是集中在双非孕妇在香港所生的子女是否享有居港权。  博客 

点击邮件名称可预览样本。
每日要闻速递
投资有路
  • 中国中国
  • 亚洲
  • 美国美国
  • 欧洲欧洲
  • US Most Actives
热门汇率
美元(USD) 6.2992
欧元(EUR) 8.3367
日元(JPY) 0.0812

在线外汇换算

热门文章点击排行

  • 资讯
  • 投资